论文部分内容阅读
采用０、７、２８天３针免疫程序接种ＨＦＲＳⅠ型灭活疫苗，１年后加强１针，采用间接免疫荧光法（ＩＦＡＴ）和微量细胞病变中和试验（ＭＣＰＫＮＴ）法分别检测血清荧光和中和抗体。本次研究共全程接种１０１７８人，对照１６１５９人。全程接种后两周荧光抗体阳性率为９８．５５％（６８／６９），中和抗体阳性率为４４．８３％，几何平均滴度分别为６９．３６和４．４４，经两个流行期的观察，接种组无发病，对照组发病１５例，人群保护率达１００％。接种疫苗１年后血清荧光抗体阳性率为２７．８７％，中和抗体阳性率为１６．６７％，几何平均滴度分别下降到１９．２０和２．８１，加强针两周后血清荧光抗体阳性率上升到８４．２１％，中和抗体阳性率上升到５６．６７％，几何平均滴度分别上升到１９．５７和５．００。
The HFRS type I inactivated vaccine was vaccinated with 0, 7 and 28 days after 3-needle immunization. One year later, one needle was instilled. Serum fluorescence and serum were detected by indirect immunofluorescence (IFAT) and microplate cell neutralization assay (MCPKNT) And antibodies. In this study, 10,178 people were vaccinated in total and 16,159 people were controlled. Two weeks after inoculation, the positive rate of fluorescent antibody was 98.55% (68/69), the positive rate of neutralizing antibody was 44.83%, the geometric mean titers were 69.36 and 4.44 respectively. After two epidemic periods The observation, the vaccination group no incidence of disease in the control group of 15 cases, population protection rate of 100%. After one year of vaccination, the positive rate of serum fluorescent antibody was 27.87%, the positive rate of neutralizing antibody was 16.67%, the geometric mean titer decreased to 19.20 and 2.81 respectively, and the serum fluorescent antibody The positive rate rose to 84.21%, the positive rate of neutralizing antibody increased to 56.67%, and the geometric mean titers increased to 19.57 and 5.00 respectively.